COVID-19 Cases “Drastically’ Dropping in India Leading to Glut of Antivirals Remdesivir & Favipiravir

COVID-19 Cases “Drastically’ Dropping in India Leading to Glut of Antivirals Remdesivir & Favipiravir

With the COVID-19 pandemic conditions improving in India according to some local reports, the demand for antiviral drugs Remdesivir and Favipiravir, used to treat moderate and severe cases of the disease is now on the wane leading to gluts. There is a glut of these drugs and with a shelf-life of three months, a good amount of product faces expiry. Pharmacy chemists apparently procure such drugs in advance and if the pharma companies don’t accept returns, the local Indian firms will suffer economic loss. Consequently, a representative form the All India Organization of Chemists and Druggists sent a letter to the executives of manufacturers of both Remdesivir and Favipiravir requesting that they accept returns. Given the association supports industry, they implore that the companies support them in this matter. The intermediaries in the supply chain may get squeezed badly if COVID-19 cases decline further. Overall, it's good news for India.

‘Compelling’ to Pay Upfront

The letter communicated, “Most of our members were compelled to purchase Remdesivir and Favipiravir drugs on advance payment. But in the recent past, owing to the drastic fall in the number of COVID-19 positive c...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee